Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

By Vandana Singh13 days ago

  • Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million ...

Full story available on Benzinga.com

Continue read on benzinga.com